Aarti Drugs Ltd

Aarti Drugs Ltd

Aarti Drugs Ltd announced leadership transition to strengthen governance and ensure long-term strategic growth. The Board approved elevation of Shri Rashesh C. Gogri to Chairman in addition to his existing role as Managing Director and appointment of Shri Adhish P. Patil as Managing Director, both effective October 1, 2026. Shri Prakash M. Patil will retire as Chairman, Managing Director & CEO, with leadership transition effective October 1, 2026.

Aarti Drugs Ltd

Aarti Drugs Ltd announces changes in its directorate, including the retirement of Prakash M. Patil as Chairman, Managing Director, and CEO, and the appointment of Rashesh C. Gogri as Chairman and Adhish P. Patil as Managing Director. Other executive and independent directors are also appointed or re-appointed.

Aarti Drugs Ltd

Aarti Drugs Ltd announced its audited standalone and consolidated financial results for the quarter ended June 30, 2026, with a profit before exceptional items and tax of ₹6,994. The company reported a revenue from operations of ₹70,278 and a total income of ₹72,030. The financial results were approved by the Board of Directors in their meeting held on July 31, 2026.

Aarti Drugs Ltd

Aarti Drugs Ltd has announced its financial results for the quarter ended June 30, 2026, with a standalone profit before exceptional items and tax of Rs. 6,994, and a total tax expense of Rs. 1,700. The company has reviewed and approved the results by its Audit Committee and Board of Directors.

Aarti Drugs Ltd

Aarti Drugs Ltd has scheduled a quarterly earnings conference call for August 3, 2026, to discuss its financial performance for the quarter ended June 30, 2026.

Aarti Drugs Ltd

Aarti Drugs Ltd has scheduled a board meeting on July 31, 2026, to consider and approve financial results for the quarter ended June 30, 2026.